PLUS THERAPEUTICS Inc. Watch

from 8-K 38 pages Plus Therapeutics, Inc. Equity Distribution Agreement

from 8-K 38 pages Plus Therapeutics, Inc. Equity Distribution Agreement

from SC 13G/A 1 page Joint Filing Agreement /S/ Dr. Andrew Brenner Dr. Andrew Brenner /S/ Dr. William Phillips Dr. William Phillips /S/ Dr. Ande Bao Dr. Ande Bao Nanotx, Corp., By: /S/ Dr. Andrew Brenner Dr. Andrew Brenner, President

from SC 13G/A 1 page Joint Filing Agreement /S/ Dr. Andrew Brenner Dr. Andrew Brenner /S/ Dr. William Phillips Dr. William Phillips /S/ Dr. Ande Bao Dr. Ande Bao Nanotx, Corp., By: /S/ Dr. Andrew Brenner Dr. Andrew Brenner, President

from 8-K 39 pages Plus Therapeutics, Inc. Equity Distribution Agreement

from SC 13G 1 page Joint Filing Agreement /S/ Andrew Brenner Dr. Andrew Brenner /S/ William Phillips Dr. William Phillips /S/ Ande Bao Dr. Ande Bao Nanotx, Corp., By: /S/ Andrew Brenner Dr. Andrew Brenner, President

from S-1/A 42 pages Shares of Common Stock, Series V Warrants (Exercisable for Shares), and Series U Warrants (Exercisable for Shares) of Plus Therapeutics, Inc. Underwriting Agreement

from 8-K 4 pages 1. Dealer-Manager Agreement Amendments. A. References in the Introductory Paragraph and Section 1(a) of the Dealer Manager Agreement to 200 Rights Warrants Shall Be Replaced With 1,050 Rights Warrants Such That Each Unit Shall Consist of One Right Share and 1,050 Rights Warrants. B. the Definition of “Expiration Date” in Section 1(d) Is Hereby Amended to Be Changed From 5:00 P.M., New York City Time, on July 13, 2018 to 5:00 P.M., New York City Time, on July 20, 2018. C. a New Section 22 Is Hereby Inserted Into the Dealer-Manager Agreement Following Section 21 of the Dealer-Manager Agreement and Such Section 22 Shall State as Follows

from POS AM 4 pages 1. Dealer-Manager Agreement Amendments. A. References in the Introductory Paragraph and Section 1(a) of the Dealer Manager Agreement to 200 Rights Warrants Shall Be Replaced With 621 Rights Warrants Such That Each Unit Shall Consist of One Right Share and 621 Rights Warrants. B. References in the Introductory Paragraph to 25,000 Units Shall Be Replaced With 20,000 Units. C. the Definition of “Expiration Date” in Section 1(d) Is Hereby Amended to Be Changed From 5:00 P.M., New York City Time, on July 13, 2018 to 5:00 P.M., New York City Time, on July 20, 2018. D. a New Section 22 Is Hereby Inserted Into the Dealer-Manager Agreement Following Section 21 of the Dealer-Manager Agreement and Such Section 22 Shall State as Follows

from POS AM 36 pages Cytori Therapeutics, Inc. Dealer-Manager Agreement

from S-1/A 36 pages Cytori Therapeutics, Inc. Dealer-Manager Agreement

from S-1/A 35 pages Form of Cytori Therapeutics, Inc. Dealer-Manager Agreement , 2017

from 8-K 36 pages Cytori Therapeutics, Inc. Underwriting Agreement

from S-1/A 2 pages Form of Cytori Therapeutics, Inc. Dealer-Manager Agreement , 2016

from 8-K 38 pages 7,020,000 Shares of Common Stock Par Value $0.001 1,053,000 Over-Allotment Shares Cytori Therapeutics, Inc. Underwriting Agreement

from 8-K 37 pages 4,000,000 Shares Cytori Therapeutics, Inc. Common Stock ($0.001 Par Value Per Share) Underwriting Agreement